New hope for Treatment-Resistant depression: Fast-Acting drug trial launches
NCT ID NCT06511908
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether a new drug called HNK can quickly improve symptoms in people with major depression that hasn't responded to other treatments. About 50 adults aged 18 to 70 will receive four infusions of HNK and four of a placebo over several weeks, with their depression levels monitored closely. The goal is to see if HNK works faster than current options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHAVIORAL SYMPTOMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a soap Opera–Style parenting program curb teen depression and suicide?
- Could a Web-Based therapy ease common mental health struggles?
- Your voice may hold clues to depression – a new device listens in
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Could the sound of your voice reveal depression?
- Mind-Body physio program aims to tackle chronic pain and depression together